4P-Pharma at the 3rd International Symposium Research on Healthy Ageing – Longevity Symposium

A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” will be presented during the 3rd International Symposium Research on Healthy Ageing – Longevity Symposium in Institut Pasteur de Lille, France, December 11th-12th 2019, by our Research Assistant, Coralie Meurot (PhD student).

For further information, please feel free to contact our R&D team, Coralie Meurot, Jérôme Breton and Céline Martin via e-mail.

4P-Pharma will attend the 10th DDIP, November 28th-29th 2019 – Barcelona, Spain

We’re glad to announce that Céline Martin, 4P-Pharma’s R&D Manager will speak during  the 10th Drug Discovery Innovation Programme (10th DDIP) organized by the World BI, November 28th-29th 2019, at Barcelona, Spain: “Pharmaceutical Development Through A Rapid Value Creation Business Model”.

To learn more about 4P-Pharma, our pipeline and our partnerships, please feel free to contact Céline or Roselina Lam, our Business Developer, via email.

4P-Pharma presents 4P-004 data at the ACR/ARP Annual Meeting in Atlanta

A poster on 4P-004 entitled “Protective Effects of Intra-Articular Formulated Liraglutide in Osteoarthritis: Preclinical Studies” (#1973) will be presented during the ACR/ARP Annual Meeting in Atlanta, Georgia November 8 – 13, 2019, by Pr. Francis Berenbaum (Professor of Rheumatology at Sorbonne University, in Paris (France)).

For further information, please click on the following link:

 

4P-Pharma est dans La Voix Du Nord

Revital Rattenbach, Présidente de 4P-Pharma, présente 4P-Pharma dans une interview avec La Voix Du Nord. Un grand merci aux équipes de BPIfrance et BPIfrance Excellence, de Eurasanté, de l’Institut Pasteur de Lille et de la Région Hauts-de-France pour leur soutien.

 

4P-Pharma dans la Tribune

Revital Rattenbach, Présidente de 4P-Pharma, et le Prof. Francis Berenbaum, Professeur de rhumatologie à Sorbonne Université, présentent dans une interview pour “Paroles d’Experts” de la Tribune, 4P-004, une nouvelle molécule thérapeutique visant à enrayer la progression de l’arthrose en vu d’un développement clinique dès 2020.